| __timestamp | BioCryst Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 14400000 |
| Thursday, January 1, 2015 | 1896000 | 33800000 |
| Friday, January 1, 2016 | 2699000 | 35900000 |
| Sunday, January 1, 2017 | 1702000 | 1254000 |
| Monday, January 1, 2018 | 471000 | 4889000 |
| Tuesday, January 1, 2019 | 4101000 | 7400000 |
| Wednesday, January 1, 2020 | 1676000 | 10100000 |
| Friday, January 1, 2021 | 7264000 | 14300000 |
| Saturday, January 1, 2022 | 6594000 | 23200000 |
| Sunday, January 1, 2023 | 4661000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Neurocrine consistently outpaced BioCryst, with its cost of revenue peaking at nearly $40 million in 2023, a staggering 750% increase from 2014. In contrast, BioCryst's cost of revenue showed a more modest growth, reaching approximately $7.3 million in 2021, a 5,860% increase from its 2014 figure. This disparity highlights Neurocrine's aggressive expansion and investment in revenue-generating activities. However, BioCryst's leaner cost structure may suggest a more cautious approach, potentially focusing on strategic investments. As the biotech industry evolves, understanding these financial dynamics offers valuable insights into each company's operational strategies and market positioning.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Neurocrine Biosciences, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Neurocrine Biosciences, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.